Denosumab versus zoledronic acid in patients with bone metastases from solid tumors other than breast and prostate cancers or multiple myeloma: A number needed to treat (NNT) analysis.
G. E. Richardson
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
T. E. Ciuleanu
Honoraria - Amgen
L. Costa
Consultant or Advisory Role - Amgen; Novartis; Roche
Research Funding - Amgen; Novartis
S. J. M. Gans
No relevant relationships to disclose
J. Á. Garcia Saenz
No relevant relationships to disclose
V. Hirsh
Consultant or Advisory Role - Amgen
V. Hungria
No relevant relationships to disclose
M. Krzakowski
No relevant relationships to disclose
C. Manegold
Honoraria - Amgen
H. Nahi
No relevant relationships to disclose
S. Novello
No relevant relationships to disclose
A. L. Petzer
Consultant or Advisory Role - Amgen
M. E. Rader
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
P. Solal-Celigny
Research Funding - Amgen
S. Vadhan-Raj
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
J. F. Vansteenkiste
Research Funding - Amgen
P. J. Woll
Consultant or Advisory Role - Amgen
C. Ke
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
K. Chung
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
H. Yeh
Employment or Leadership Position - Amgen
Stock Ownership - Amgen